Kiniksa Pharmaceuticals, Ltd. — 2018 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018; filed March 12, 2019. This is an annual report, not a standalone fourth-quarter report. Kiniksa is a clinical-stage biopharmaceutical company developing treatments for autoimmune and autoinflammatory diseases. It had no product-sales revenue.
Key financial metrics
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $86.6 million | $56.4 million |
| General and administrative expense | $21.6 million | $9.0 million |
| Total operating expenses / operating loss | $108.2 million | $65.4 million |
| Interest income | $4.7 million | $0.5 million |
| Net loss | $103.2 million | $64.9 million |
| Net loss per share, basic and diluted | $3.49 | $35.85 |
| Cash, cash equivalents and short-term investments, year-end | $307.3 million | $45.6 million |
| Working capital, year-end | $271.2 million | $29.7 million |
| Net cash used in operating activities | $81.0 million | $50.2 million |
Losses increased as the company expanded research, trials and operations. R&D expense rose 54% and G&A expense rose 138% year over year. With no revenue, gross profit and operating margins are not meaningful. The balance sheet reports $42.7 million of total liabilities; it does not show borrowings or a debt balance. The company reported no off-balance-sheet arrangements.
Cash and investments comprised $72.0 million in cash and cash equivalents and $235.3 million in short-term investments at year-end. The 2018 operating cash outflow was partly offset by financing: the IPO and over-allotment generated approximately $155.5 million net, and Series C preferred shares generated approximately $190.8 million net. Investing cash outflow of $239.2 million primarily reflected purchases of short-term investments. Management said year-end resources, including the February–March 2019 financing proceeds, were expected to fund operations and capital needs for at least 12 months from the financial-statement issuance date.
Business progress and material changes
- Rilonacept: Kiniksa was enrolling RHAPSODY, a pivotal global Phase 3 trial for recurrent pericarditis, and expected enrollment completion in the second half of 2019 and top-line results in the second half of 2020. The open-label Phase 2 trial had completed enrollment. Interim results from 12 symptomatic subjects showed lower reported pain and CRP, but the small, uncontrolled interim dataset is not confirmatory evidence.
- Mavrilimumab: The global Phase 2 trial for giant cell arteritis had begun dosing. The FDA had lifted an initial U.S. clinical hold after receiving requested information about the delivery device. Management expected enrollment completion in the second half of 2019 and top-line results in the second half of 2020.
- KPL-716: Single-dose Phase 1 results in atopic dermatitis were described as well tolerated and showed exploratory signals on itch and disease-severity measures. The company planned a prurigo nodularis Phase 2a/2b study and a multi-indication pilot study in the first half of 2019.
- Preclinical programs: KPL-404 remained in preclinical development, with an IND filing planned for the second half of 2019 and Phase 1 initiation in the first half of 2020. KPL-045’s further development was under review.
- After year-end, Kiniksa completed a follow-on offering and concurrent private placement, with approximately $83.0 million net proceeds including the partial over-allotment. It also acquired Primatope in March 2019; disclosed consideration included $10.0 million at closing and potential milestone payments of up to $8.0 million, of which $5.0 million had been achieved and paid at closing.
Outlook, risks and unusual items
Management expected substantial future losses and increased R&D spending as trials advanced. The company had no approved products for its own commercial programs and had not completed a pivotal trial or established commercial-scale manufacturing or sales operations. It expected to need additional capital beyond its stated 12-month runway; future financing could dilute shareholders or require less favorable terms.
- Development risks include trial failure or delay, uncertain regulatory decisions, patient-enrollment challenges and adverse events. Rilonacept’s Phase 2 study included one treatment-related serious adverse event, a skin abscess that led to discontinuation; infections are a known labeled risk. Mavrilimumab carries a theoretical pulmonary alveolar proteinosis risk based on nonclinical findings.
- Manufacturing depends on third parties and single-source supply for key clinical materials. The mavrilimumab manufacturing transfer required alternative media and feed components, adding execution risk.
- Licensing arrangements bring contingent obligations: up to $27.5 million of regulatory milestones and an equal profit split with Regeneron for rilonacept sales; mavrilimumab also carries milestone and tiered royalty obligations. The filing reports $15.0 million of accrued MedImmune milestones at year-end.
- Intellectual-property protection for rilonacept is a concern: the U.S. composition-of-matter patent was expected to expire in 2019, excluding possible adjustments, and the company anticipated relying on regulatory exclusivity if available.
- The company reported no material legal proceedings. The independent auditor gave an unqualified opinion on the financial statements. Management concluded disclosure controls were effective at the reasonable-assurance level; the filing omitted management’s internal-control report under the transition relief for newly public companies.
Important facts for investors to verify
- Progress, safety and final results for RHAPSODY and the mavrilimumab and KPL-716 trials, including whether stated enrollment and data timelines were met.
- Cash runway assumptions, subsequent cash use, and the net proceeds and dilution from 2019 financing and Primatope acquisition consideration.
- Manufacturing capacity, supply continuity and successful mavrilimumab process transfer, including any additional costs or delays.
- Milestone, royalty and profit-sharing obligations under the company’s licenses, and the practical value and duration of relevant patent and regulatory exclusivity.
- Voting control and potential dilution: the filing describes a multi-class share structure in which Class B shares have ten votes each, while Class A1 and B1 shares have no votes unless converted.